Доступ предоставлен для: Guest
Портал Begell Электронная Бибилиотека e-Книги Журналы Справочники и Сборники статей Коллекции
Critical Reviews™ in Therapeutic Drug Carrier Systems
Импакт фактор: 2.9 5-летний Импакт фактор: 3.72 SJR: 0.573 SNIP: 0.551 CiteScore™: 2.43

ISSN Печать: 0743-4863
ISSN Онлайн: 2162-660X

Том 36, 2019 Том 35, 2018 Том 34, 2017 Том 33, 2016 Том 32, 2015 Том 31, 2014 Том 30, 2013 Том 29, 2012 Том 28, 2011 Том 27, 2010 Том 26, 2009 Том 25, 2008 Том 24, 2007 Том 23, 2006 Том 22, 2005 Том 21, 2004 Том 20, 2003 Том 19, 2002 Том 18, 2001 Том 17, 2000 Том 16, 1999 Том 15, 1998 Том 14, 1997 Том 13, 1996 Том 12, 1995

Critical Reviews™ in Therapeutic Drug Carrier Systems

DOI: 10.1615/CritRevTherDrugCarrierSyst.v26.i4.10
pages 333-372

Paclitaxel in Cancer Treatment: Perspectives and Prospects of its Delivery Challenges

Somnath Singh
Department of Pharmacy Sciences, School of Pharmacy and Health Professions, Creighton University, Omaha, Nebraska
Alekha K. Dash
Creighton University

Краткое описание

Paclitaxel (PTX) is a potent anticancer agent whose clinical usefulness is marred by a delivery problem that is caused by its unfavorable pharmacokinetic and physical properties. Paclitaxel is currently formulated in a mixture of Cremophor EL and ethanol, which is diluted 5−20 times with normal saline or 5% dextrose prior to administration via slow infusion to avoid precipitation in plasma. Many adverse reactions to the PTX formulation have been reported because of the presence of Cremophor EL, including hypersensitivity reactions, nephrotoxicity, and neurotoxicity. Cremophor EL also causes vasodilation, labored breathing, lethargy, hypotension, and leaching of plasticizers, such as diethylhexylpthalate, from the polyvinylchloride infusion bags/sets. Significant research efforts have been conducted to develop an alternative formulation approach to increase the aqueous solubility of PTX without using Cremophor, thereby decreasing its toxicity. This article reviews the various investigated formulation approaches including pastes; liposomes; conjugates with antibodies, peptides, and fatty acids; nanospheres and microspheres; cyclodextrin complexes; emulsions; mucoadhesive gel; prodrugs; and nanoparticulate systems. The pros and cons of each approach are also discussed. Finally, this review concludes with a discussion of nanoparticulate delivery, which is the most promising PTX delivery system of the future because it incorporates the benefits of other approaches such as conjugation, complexation, and prodrugs.

Articles with similar content:

Microemulsions: Applications in Transdermal and Dermal Delivery
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.24, 2007, issue 6
Vandana B. Patravale, Abhijit A. Date
Pharmaceutical Approaches to Preparing Pelletized Dosage Forms Using the Extrusion-Spheronization Process
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.24, 2007, issue 1
Maria Gerald Rajan, James R. Johnson, Atul J. Shukla, Namrata R. Trivedi
Controlled Release from Crosslinked Degradable Networks
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.19, 2002, issue 4-5
Kristi S. Anseth, Kelly A. Davis
Transcending the Skin Barrier to Deliver Peptides and Proteins Using Active Technologies
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.29, 2012, issue 4
Haripriya Kalluri, Anushree Herwadkar, Neha Singh, Ajay K. Banga, Advait Badkar
Lipids and Surfactants: The Inside Story of Lipid-Based Drug Delivery Systems
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.35, 2018, issue 2
Seema Kohli, Vikas Pandey